Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Stage II Uterine Corpus Cancer: full-pipeline trial registry

1 of 5 indexed Stage II Uterine Corpus Cancer trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Stage II Uterine Corpus Cancer: 5 US clinical trials tracked, 1 recruiting.

Stage II Uterine Corpus Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 4 of these trials.

Enrollment posture brief

Registry condition stage-ii-uterine-corpus-cancer

OPEN 1 | RECR 20% | LATE 1 | EARLY 1 | RANK #3391 | SPON 4

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Stage II Uterine Corpus (th…20%
Open-enrollment share among volume-matched conditions near Stage II Uterine Corpus Cancer

Stage II Uterine Corpus Cancer lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage II Uterine Corpus Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage II Uterine Corpus Cancer is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage II Uterine Corpus Cancer research.

    Gynecologic Oncology Group accounts for 4 of 5 trials (80%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Typical Stage II Uterine Corpus Cancer enrolment sits around 243 participants.

    Median target enrolment is 243 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Stage II Uterine Corpus Cancer research leans observational.

    2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1

Top Sponsors

Gynecologic Oncology Group 4 trials
University of Utah 1 trials

Named interventions

Most-linked intervention names on Stage II Uterine Corpus Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Study of Socioeconomic and Demographic Variables Other
2 trials
Microarray Analysis Genetic
1 trials
Immunohistochemistry Staining Method Other
1 trials
Medroxyprogesterone Drug
1 trials
Short course vaginal cuff brachytherapy Radiation
1 trials
Vaginal Cuff Brachytherapy Radiation
1 trials
Diagnostic Laboratory Biomarker Analysis Other
1 trials

US sites by state

Facility locations filed on Stage II Uterine Corpus Cancer trials. A trial with sites in several states counts in each.

Pennsylvania 4 trials
Utah 1 trials
Texas 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stage II Uterine Corpus Cancer page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage II Uterine Corpus Cancer condition card totals 5 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.